Form 4 for HAE HAEMONETICS CORP
Accepted 2024-09-03 00:00:00 ET · period of report 2024-08-29 · accession 0001127602-24-023305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-03 | 2024-08-29 | HAE | Simon, Christopher | Pres, CEO, Dir | J - Other | $75.56 | -39.7K | 322.8K | -11% | -$3.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-29 | J | D | 39,704 | $75.56 | 322,838 | D | — | — | (F1) On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee. (F2) This number includes unvested restricted stock units previously reported. |